Aktie A2PKLC ARMATA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Armata Pharmaceuticals, Inc.

Aktien

A2PKLC

US04216R1023

ARMP

Markt geschlossen - Nyse
Andere Börsenplätze
 22:10:00 18.04.2024 		% 5 Tage % 1. Jan.
2.55 USD +2.00% Intraday Chart für Armata Pharmaceuticals, Inc. -22.96% -21.30%
21.03. Armata Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
21.03. Armata Pharmaceuticals, Inc. meldet Ergebnis für das vierte Quartal zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Armata Pharmaceuticals, Inc. Announces CFO Changes
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Microcap Value Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PKLC Aktie
  4. Nachrichten Armata Pharmaceuticals, Inc.
  5. Andere Sprachen